Wolfe Research analyst Doug Schenkel upgraded Repligen (NASDAQ: RGEN) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Upgrades

Repligen (RGEN) PT Lowered to $940 at Truist SecuritiesApril 29, 2025 4:03 PM Repligen (RGEN) PT Lowered to $914 at JefferiesApril 29, 2025 3:58 PM Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'April 29, 2025 2:54 PM